Ertugliflozin
Steglatro (ertugliflozin) is an oral prescription medication used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It belongs to a class of drugs called SGLT2 inhibitors that work by helping the kidneys remove glucose from the bloodstream through urine. This medication is typically prescribed when blood sugar cannot be controlled through lifestyle changes alone.
Steglatro is a once-daily oral diabetes medication that helps control blood sugar levels in adults with type 2 diabetes by causing the kidneys to excrete excess glucose through urine.
Key facts at a glance
- RxNorm
- 1992811
- Generic
- Steglatro
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Steglatro is indicated for improving glycemic control in adults with type 2 diabetes mellitus. It is used as an adjunct to diet and exercise and may be prescribed alone or in combination with other antidiabetic medications such as metformin, insulin, or other oral agents.
Steglatro belongs to the SGLT2 (sodium-glucose cotransporter-2) inhibitor class. It works by blocking the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By inhibiting this process, Steglatro causes excess glucose to be filtered out of the blood and excreted through urine, thereby lowering blood glucose levels.
Steglatro is not indicated for use in patients with type 1 diabetes or those with diabetic ketoacidosis. Common side effects may include genital yeast infections, urinary tract infections, and increased urination. Rare but serious risks include ketoacidosis and necrotizing fasciitis of the perineum (Fournier's gangrene). Patients should be monitored for kidney function during treatment, and adequate hydration is recommended. Steglatro may cause hypotension, especially in patients taking diuretics or with renal impairment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy